CRC
CTD - Clinical Trials Data
Abbreviations
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer
Randomized Phase III Study of Panitumumab With FOLFIRI Compared With FOLFIRI Alone As Second-Line Treatment in Patients With mCRC
FDA Drug Approval Summary: Panitumumab
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Randomized, Phase III Trial of Panitumumab With FOLFOX4 Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer
© 2021 - 2024 | MedAgora Consulting srl